BioCentury
ARTICLE | Company News

DanDrit Biotech USA, Oxford BioMedica, myTomorrows cancer news

February 17, 2014 8:00 AM UTC

Online patient platform myTomorrows will offer patients access to DanDrit's MelCancerVac and to an undisclosed therapeutic cancer vaccine from Oxford BioMedica. MelCancerVac is a dendritic cell-based vaccine that has completed Phase II testing to treat colorectal cancer and non-small cell lung cancer (NSCLC). myTomorrows said DanDrit's vaccine will be available worldwide, except in the U.S., Canada and Singapore. DanDrit plans to start a Phase IIb trial later this year and declined to disclose financial terms.

Oxford BioMedica is developing preventive vaccine TroVax, a modified vaccinia Ankara (MVA) against 5T4, which is in Phase II testing to treat colorectal, renal and prostate cancer. Oxford BioMedica declined to disclose details, including vaccine specifics. myTomorrows said Oxford BioMedica's vaccine will be available worldwide upon request by doctors. ...